Luxembourg
· Delayed Price · Currency is EUR · Price in USD Oneness Biotech Statistics
Total Valuation
Oneness Biotech has a market cap or net worth of EUR 674.77 million. The enterprise value is 531.06 million.
| Market Cap | 674.77M |
| Enterprise Value | 531.06M |
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.25% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 8.15% |
| Owned by Institutions (%) | 5.17% |
| Float | 305.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 192.67 |
| PB Ratio | 2.37 |
| P/TBV Ratio | 2.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -18.74 |
| EV / Sales | 151.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -40.61 |
Financial Position
The company has a current ratio of 11.81, with a Debt / Equity ratio of 0.04.
| Current Ratio | 11.81 |
| Quick Ratio | 11.44 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.77 |
| Interest Coverage | -90.22 |
Financial Efficiency
Return on equity (ROE) is -9.10% and return on invested capital (ROIC) is -15.31%.
| Return on Equity (ROE) | -9.10% |
| Return on Assets (ROA) | -3.95% |
| Return on Invested Capital (ROIC) | -15.31% |
| Return on Capital Employed (ROCE) | -7.16% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 81,445 |
| Profits Per Employee | -658,996 |
| Employee Count | 43 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.80 |
Taxes
In the past 12 months, Oneness Biotech has paid 93,979 in taxes.
| Income Tax | 93,979 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.36% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -14.36% |
| 50-Day Moving Average | 8.65 |
| 200-Day Moving Average | 10.18 |
| Relative Strength Index (RSI) | 47.54 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oneness Biotech had revenue of EUR 3.50 million and -28.34 million in losses. Loss per share was -0.06.
| Revenue | 3.50M |
| Gross Profit | 1.08M |
| Operating Income | -21.78M |
| Pretax Income | -28.64M |
| Net Income | -28.34M |
| EBITDA | -14.01M |
| EBIT | -21.78M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 157.94 million in cash and 10.06 million in debt, giving a net cash position of 147.89 million.
| Cash & Cash Equivalents | 157.94M |
| Total Debt | 10.06M |
| Net Cash | 147.89M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 284.16M |
| Book Value Per Share | 0.58 |
| Working Capital | 152.88M |
Cash Flow
In the last 12 months, operating cash flow was -12.48 million and capital expenditures -595,718, giving a free cash flow of -13.08 million.
| Operating Cash Flow | -12.48M |
| Capital Expenditures | -595,718 |
| Depreciation & Amortization | 7.76M |
| Net Borrowing | -1.16M |
| Free Cash Flow | -13.08M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 30.88% |
| Operating Margin | -621.89% |
| Pretax Margin | -817.87% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oneness Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.25% |
| Shareholder Yield | -0.25% |
| Earnings Yield | -4.20% |
| FCF Yield | -1.94% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Oneness Biotech has an Altman Z-Score of 15.59 and a Piotroski F-Score of 2.
| Altman Z-Score | 15.59 |
| Piotroski F-Score | 2 |